UNSPSC 51392306: Xamoterol fumarate

This classification denotes a beta-adrenergic agonist 2C16H25N3O5.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N87007N668, chemically known as ici-118,587 hemifumarate, but more generally known as xamoterol fumarate, which bears US NIH Compound Identifier 6917710. European Medicines Agency schedules Xamoterol fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05144MIG. Most nations, for tariff and trade purposes, schedule xamoterol fumarate under HS 29349990 and SITC 51579.

As of Q4 2014, XAMOTEROL FUMARATE remains US FDA's Preferred Term for this commodity. SMILES: C1CC(CCC1O)OCC(CNCCNC(=O)N2CCOCC2)O.C1CC(CCC1O)OCC(CNCCNC(=O)N2CCOCC2)O.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51392306 Xamoterol fumarate is a Commodity code that shows minimal recent state and local procurement activity aligned with its nominal scope. The two recent opportunities tagged under this code involve naloxone procurement and pharmacy benefit management strategy, neither of which concerns xamoterol fumarate—a beta-adrenergic agonist pharmaceutical. The mismatch between code classification and actual solicitation scope suggests either miscoding by issuing bodies or use of the code as a placeholder in early-stage market research. State and local governments sourcing under this code, when they do, appear to be county health departments and state health agencies managing pharmaceutical supply chains and addiction-response initiatives.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB with a due date of July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building in Sanford and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, seeking vendor experience with direct contracting outside traditional pharmacy benefit manager and group purchasing organization channels. The limited and non-aligned recent activity under this code suggests low current pursuit potential for vendors in xamoterol fumarate supply unless procurement demand shifts or coding accuracy improves across state and local issuing bodies.